ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011
News
FDA to Study Online Drug Marketing
By Angie Drakulich
FDA is collecting public comments on a series of studies that the agency plans to conduct on online direct-to-consumer promotion of prescription drug products, according to an announcement in the Federal Register.
Teva Snatches Cephalon from Valeant
By Rich Whitworth
Israel-based Teva Industries seals deal to acquire Cephalon for $6.8 billion.
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs
By Patricia Van Arnum
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs.
Excipient-Certification Standards Presented for Comment
By Erik Greb
The IPEC is soliciting public comment about a draft plan for the independent certification of manufacturers and suppliers of pharmaceutical excipients.
Federal Appeals Court Lifts Ban on Funding for Embryonic Stem Cell Research
By Amy Ritter
A federal appeals court has lifted a ban on federal funding for embryonic stem cell research.
Week of May 5, 2011: Company and People Notes: Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Regulatory Roundup: FDA Calling on Industry to Provide Feedback on Existing Regulations
FDA Calling on Industry to Provide Feedback on Existing Regulations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here